ArticleJournal of healthcare leadership2026
Evaluating the Zero-Markup Drug Policy's Effects on Financial Burden and Pharmaceutical Channel Migration: A Structural Variation and Interrupted Time Series Analysis from Hubei, China.
Article in Journal of healthcare leadership, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study evaluates the impact of China's zero-markup drug policy (ZMDP) on patients' financial burden and pharmaceutical purchasing channel migration, using Yichang City in Hubei Province as a case study. Methods: We analyzed data from 108 hospitals (January 2016 - December 2019) and monthly medical insurance reimbursement records. Structural variation analysis (SVA) and interrupted time series analysis (ITSA) with month-of-year fixed effects and counterfactual predictions were employed to assess changes in outpatient costs, inpatient costs, and pharmacy purchase outcomes (total expenditure, purchase volume, and average cost per purchase) before and after the policy implementation (August 2017). Results: Drug cost proportions declined from 41.67% to 37.14% for outpatient and from 34.97% to 27.60% for inpatient services. ITSA revealed a marginally significant immediate outpatient cost reduction (β Conclusion: The ZMDP effectively reduced hospital drug expenditures but triggered cost substitution toward diagnostic services and pharmaceutical channel migration to retail pharmacies. For healthcare leaders, these findings suggest that vertical price regulation without horizontal integration across care settings may simply relocate costs. Future reforms should incorporate integrated prescription monitoring and complementary pricing reforms to achieve sustainable financial protection. Strengths and Limitations of This Study: This study has several strengths. The use of ITSA with month-of-year fixed effects and counterfactual predictions controls for seasonal patterns and quantifies policy effect magnitudes. Structural variation analysis complements this by measuring expenditure redistribution across service categories. Placebo tests further support the robustness of findings for most outcomes. Limitations include the single-group ITSA design without a concurrent control group and the single-city setting, which limit causal attribution and generalizability. The study period ends in 2019 due to the COVID-19 pandemic, constraining long-term observation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.